MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Voyager Therapeutics Inc

Gesloten

3.11 -8.8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.09

Max

3.41

Belangrijke statistieken

By Trading Economics

Inkomsten

-25M

-34M

Verkoop

-18M

6.3M

K/W

Sectorgemiddelde

6.415

63.778

EPS

-0.59

Winstmarge

-549.331

Werknemers

172

EBITDA

-25M

-37M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+343.7% upside

Dividenden

By Dow Jones

Volgende Winsten

12 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-31M

202M

Vorige openingsprijs

11.91

Vorige sluitingsprijs

3.11

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Voyager Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 okt 2024, 21:31 UTC

Top Nieuws

AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com

Peer Vergelijking

Prijswijziging

Voyager Therapeutics Inc Prognose

Koersdoel

By TipRanks

343.7% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.13 USD  343.7%

Hoogste 30 USD

Laagste 9 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Voyager Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technische score

By Trading Central

3.26 / 3.74Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.